All Title Author
Keywords Abstract

-  2015 

Knockout Grp78 expression increases the sensitivity of hepatoma cells to erlotinib

DOI: 10.6040/j.issn.1671-7554.0.2014.811

Keywords: 肝癌,Grp78,厄洛替尼,
,Grp78,Hepatocellular carcinoma

Full-Text   Cite this paper   Add to My Lib



[1]  Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain[J]. Plos Medicine, 2005, 29(3):57-62.
[2]  Lee E, Nichols P, Spicer D, et al. GRP78 as a novel predictor of responsiveness to chemotherapy in breast cancer[J]. Cancer Res, 2006, 66(16):7849-7853.
[3]  Metzger B, Chambeau L, Begon DY, et al. The human epidermal growth factor receptor (EGFR) gene in European patients with advanced colorectal cancer harbors infrequent mutations in its tyrosine kinase domain[J]. BMC Med Genet, 2011, 12: 144. doi: 10.1186/1471-2350-12-144.
[4]  徐立, 张昌卿, 冯凯涛, 等. 肝细胞癌及癌旁肝组织EGFR和EGFR vⅢ的表达及其临床意义[J]. 中山大学学报: 医学科学版, 2006, 27(4): 467- 471. XU Li, ZHANG Changqing, FENG Kaitao, et al. Clinical significance of EGFR and EGFRvⅢ expression in tumor and liver tissue of HCC[J]. Journal of Sun Yat-sen University: Medical Sciences, 2006, 27(4): 467- 471.
[5]  Mueller KL, Powell K, Madden JM, et al. EGFR tyrosine 845 phosphorylation-dependent proliferation and transformation of breast cancer cells require activation of p38 MAPK[J]. Transl Oncol, 2012, 5(5): 327-334.
[6]  Zhang LH, Yang XL, Zhang X, et al. Association of elevated GRP78 expression with increased astrocytoma malignancy via Akt and ERK pathways[J]. Brain Res, 2011, 1371: 23-31.
[7]  Donev IS, Wang W, Yamada T, et al. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer[J]. Clin Cancer Res, 2011, 17(8): 2260-2269.
[8]  Fuchs BC, Hoshida Y, Fujii TE, et al. Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma[J]. Hepatology, 2014, 59(4): 1577-1590.
[9]  Su R, Li Z, Li H, et al. Grp78 promotes the invasion of hepatocellular carcinoma[J]. BMC Cancer, 2010, 10: 20. doi: 101186/1471-2407-10-20.
[10]  Fu R, Yang P, Wu HL, et al. GRP78 secreted by colon cancer cells facilitates cell proliferation via PI3K/Akt signaling[J]. Asian Pac J Cancer Prev, 2014, 15(17): 7245-7249.
[11]  Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population[J]. J Clin Gastroenterol, 2013, 47 Suppl:S2-S6.
[12]  Hoshi S, Yamaguchi T, Kono C, et al. Recurrence of non-small cell lung cancer after successful treatment with gefitinib-report of three cases[J]. Gan To Kagaku Ryoho, 2004, 31(8):1209-1213.
[13]  Reddy RK, Mao C, Baumeister P, et al. Endoplasmic reticulum chaperone protein GRP78 protects cells from apoptosis induced by topoisomerase inhibitors: role of ATP binding site in suppression of caspase-7 activation[J]. J Biol Chem, 2003, 278(23):20915-20924.
[14]  Tsutsumi S, Namba T, Tanaka KI, et al. Celecoxib upregulates endoplasmic reticulum chaperones that inhibit celecoxib-induced apoptosis in human gastric cells[J]. Oncogene, 2006, 25(7):1018-1029.
[15]  Lindzen M, Carvalho S, Starr A, et al. A recombinant decoy comprising EGFR and ErbB-4 inhibits tumor growth and metastasis[J]. Oncogene, 2012, 31(30): 3505-3515.
[16]  Hsu CH, Kang YK, Yang TS, et al. Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: a multicenter phase II study[J]. Oncology, 2013, 85(1): 44-52.
[17]  Thomas MB, Chadha R, Glover K, et al. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma[J]. Cancer, 2007, 110(5): 1059-1067.
[18]  Philip PA, Mahoney MR, Allmer C, et al. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer[J]. J Clin Oncol, 2005, 23(27): 6657-6663.


comments powered by Disqus